Roche/Syntex
This article was originally published in The Tan Sheet
Executive Summary
Tender offer deadline for Hoffmann La Roche's $24-per-share acquisition of Syntex is being extended -- from Aug. 24 to Aug. 31 -- while the Federal Trade Commission continues to investigate the proposed deal. Roche said Aug. 24 that it "expects that the investigation will be resolved" by Aug. 31 but can offer no assurances. Any further extensions of the tender offer will each be in one-week increments. According to the latest count, approximately 127 mil. shares of Syntex stock have been tendered. The definitive agreement between Roche and Syntex was announced May 2 and valued at about $5.3 bil. ("The Tan Sheet" May 16, p. 12). FTC made its first request for additional information dune 6 under the waiting period terms of the Hart- Scott-Rodino Act
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning